These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14060969)

  • 1. [CONTRIBUTION TO THE STUDY OF BONE METASTASES IN PROSTATE CANCER (CLINICAL FORMS AND TREATMENT)].
    PANNIER S
    Fr Med; 1963 May; 26():317-9. PubMed ID: 14060969
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rate of survival in prostatic cancer with bone metastasis].
    Kuntz D; Ryckewaert A
    Rev Fr Etud Clin Biol; 1969; 14(6):609-13. PubMed ID: 5824263
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prostatic neoplasm with skeletal metastases. Exceptional survival and disappearance of the metastases after hormone therapy].
    Filippini U
    Minerva Urol; 1969; 21(6):232-4. PubMed ID: 5403841
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate stem cell antigen is overexpressed in prostate cancer metastases.
    Lam JS; Yamashiro J; Shintaku IP; Vessella RL; Jenkins RB; Horvath S; Said JW; Reiter RE
    Clin Cancer Res; 2005 Apr; 11(7):2591-6. PubMed ID: 15814638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proceedings: Value of cyproterone in the treatment of prostatic cancers with metastases].
    Bracci U
    J Urol Nephrol (Paris); 1973 Dec; 79(12 Pt 2):405-6. PubMed ID: 4804409
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
    Ozyuvaci E; Altan A; Demir C
    Agri; 2005 Jan; 17(1):49-53. PubMed ID: 15791501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding bone metastases: the key to the effective treatment of prostate cancer.
    Fidler IJ
    Clin Adv Hematol Oncol; 2003 May; 1(5):278-9. PubMed ID: 16224421
    [No Abstract]   [Full Text] [Related]  

  • 9. Canine prostate stimulates osteoblast function using the endothelin receptors.
    LeRoy BE; Sellers RS; Rosol TJ
    Prostate; 2004 May; 59(2):148-56. PubMed ID: 15042615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
    Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.
    Hegele A; Wahl HG; Varga Z; Sevinc S; Koliva L; Schrader AJ; Hofmann R; Olbert P
    BJU Int; 2007 Feb; 99(2):330-4. PubMed ID: 17092281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone.
    Hall CL; Dai J; van Golen KL; Keller ET; Long MW
    Cancer Res; 2006 Sep; 66(17):8648-54. PubMed ID: 16951179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
    Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS
    Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
    Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
    Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormone therapy of prostatic cancer].
    Nilsson S
    Lakartidningen; 1968 Jun; 65(25):2563-70. PubMed ID: 5720284
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
    Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
    Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.